Susquehanna Fundamental Investments’s Bioventus BVS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-32,917	Closed	-$230K	–	1229
2022 Q3	$230K	Buy	+32,917	New	+$258K	﹤0.01%	1227
2022 Q1	$325K	Buy	+23,028	New	+$308K	0.01%	1231

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JIC

Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Susquehanna Fundamental Investments's BVS Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Bioventus (BVS) in Q4 2022, closing a stake of 32,917 shares — an estimated $230K sold.

Susquehanna Fundamental Investments first reported a position in BVS in Q1 2022 and held it in 2 quarters. The position peaked at $325K in Q1 2022. 85 funds tracked by Wall St. Rank hold BVS as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Bioventus position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 32,917 Bioventus shares in Q4 2022, an estimated $230K.
Susquehanna Fundamental Investments first reported a position in Bioventus in Q1 2022 and held it in 2 quarters.
Susquehanna Fundamental Investments's Bioventus position peaked at $325K in Q1 2022.
85 funds tracked by Wall St. Rank held Bioventus as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.